Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.

Arthritis and rheumatism - 1 Feb 2007

Kastbom Alf, Bratt Johan, Ernestam Sofia, Lampa Jon, Padyukov Leonid, Söderkvist Peter, Skogh Thomas

Abstract excerpt

OBJECTIVE: To determine whether a functional single-nucleotide polymorphism in the gene encoding Fcgamma receptor type IIIA (FcgammaRIIIA) correlates with the response to treatment with tumor necrosis factor alpha inhibitors in rheumatoid arthritis (RA). METHODS: The study population comprised 282 Swedish patients with RA in whom the therapeutic efficacy of conventional disease-modifying antirheumatic drugs had...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Rheumatoid

Share to Etanercept

Share to Immunoglobulin G

Share to Infliximab

Share to Receptors, IgG

Share to Receptors, Tumor Necrosis Factor

Source

Identifiers

PMID: 17265480
DOI: 10.1002/art.22390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.PMID 17265480Read ↗

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.Semantic proximity Read ↗

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.Semantic proximity Read ↗

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.Semantic proximity Read ↗

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.Semantic proximity Read ↗

Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis.Semantic proximity Read ↗

Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.Semantic proximity Read ↗

Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups.Semantic proximity Read ↗

FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.Semantic proximity Read ↗

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.Semantic proximity Read ↗

The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.Semantic proximity Read ↗

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.Semantic proximity Read ↗

Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.